Strategic Relationships

Our alliances and collaborations have enabled us to increase our scientific capabilities and facilitate the development of new technologies in order to broaden and advance our discovery platforms.

  • The Pennsylvania State University
  • ABTC Consortium
  • The National Cancer Institute
  • Sterne Kessler Goldstein & Fox
  • FDA

The Pennsylvania State University

Intellectual Property Targepeutics has a strong and growing relationship with The Pennsylvania State University. The Company has executed an exclusive license agreement with The Penn State Research Foundation for key technologies emanating from work in the lab of Dr. Debinski. At the University’s request, an agreement has been negotiated to convert Penn State’s interest into equity in Targepeutics. We are pleased to be partnering with such a reputable University with an annual research budget exceeding $440MM.

Adult Brain Tumor Consortium 

In recognition of Dr. Debinski’s record in experimental therapeutics, he andTargepeutics have been invited to participate in the Adult Brain Tumor Consortium (ABTC)  which consists of leading oncologists, neurologists and neurosurgeons. The primary goals of the ABTC are to develop scientific advances and improve therapeutic outcomes for patients with primary brain tumors. ABTC Is NCI-Funded This exemplary program is a National Cancer Institute (NCI)-funded clinical consortium of the following 10 top cancer treatment institutions with outstanding multidisciplinary expertise, innovative clinical and laboratory research capabilities, and access to a large patient population with brain tumors. Current ABTC Institutions

NCI funding enables companies sponsored by ABTC to cut clinical trial costs. Currently, Targepeutics and ABTC are jointly designing clinical protocols to quickly evaluate the toxicity and efficacy of Glioblast-13 in Phase I/Phase II clinical trials.

Sterne, Kessler, Goldstein & Fox

Targepeutics is pleased to have on its team, intellectual property attorneys of such high regard in their community. These strategists and advisors specialize in the protection, transfer and enforcement of Targepeutics’ Intellectual Property Rights. The team is lead by Dr. Jorge Goldstein and is located in Washington, D.C.

The National Cancer Institute SBIR contract The National Cancer Institute recently awarded Targepeutics a $200,000 Small Business Innovative Research (SBIR) contract to develop GB-13, the Company’s first brain cancer compound. This grant is a Phase I award and makes Targepeutics eligible to submit for up to $2 million in Phase II of the program.



Targepeutics maintains a positive working relationship through pre-IND meetings with the FDA (Food and Drug Administration), which has defined achievable milestones forGB-13’s path to clinical trials. Targepeutics will file for both Fast Track and Orphan Drug status concomitantly with its Investigational New Drug Application.

Never doubt that a small group of thoughtful and committed people can change the world, indeed it is the only thing that ever has.